US00D870129S

(12) United States Design Patent

Bhardwaj et al.

(10) Patent No.: US D870,129 S
(45) Date of Patent: ** Dec. 17, 2019

(54) **DISPLAY SCREEN WITH TRANSITIONAL GRAPHICAL USER INTERFACE**

(71) Applicant: **Innoplexus AG**, Eschborn (DE)

(72) Inventors: **Gunjan Bhardwaj**, Kornwestheim (DE); **Dileep Dharma**, Pune (IN); **Vatsal Agarwal**, Rampur (IN); **Vikram Sangat**, Pune (IN)

(73) Assignee: **INNOPLEXUS AG**, Eschborn (DE)

(**) Term: **15 Years**

(21) Appl. No.: **29/642,276**

(22) Filed: **Mar. 28, 2018**

(51) **LOC (12) Cl.** **14-04**

(52) **U.S. Cl.**
USPC **D14/486**; D14/490

(58) **Field of Classification Search**
USPC D14/485–495
CPC ... B60K 37/00; G06F 3/0481; G06F 3/04845; G06F 3/04817; G06F 17/212; G06F 19/3406; G06T 13/80; G06T 15/02
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

D634,330	S *	3/2011	Brown	D14/486
D664,981	S *	8/2012	Rai	D14/488
D665,411	S *	8/2012	Rai	D14/488
D736,230	S *	8/2015	Bork	D14/486
D751,085	S *	3/2016	Winther	D14/485
D753,157	S *	4/2016	Hau	D14/486

(Continued)

OTHER PUBLICATIONS

Innoplexus | BLOG | Innoplexus products are powered by ArangoDB, posted on Jun. 5, 2018, © Innoplexus 2019 [online], [site visited Aug. 15, 2019]. Available from Internet, <URL: https://www.innoplexus.com/blog/products-powered-by-arangodb/>.*

(Continued)

Primary Examiner — Philip S Hyder
Assistant Examiner — Cary M Robinson
(74) *Attorney, Agent, or Firm* — Ziegler IP Law Group, LLC

(57) **CLAIM**

The ornamental design of a display screen with transitional graphical user interface, as shown and described.

DESCRIPTION

FIG. **1** is a front view of a first image in a sequence of a transitional graphical user interface on a display screen;
FIG. **2** is a front view of a second image in the sequence of the transitional graphical user interface on the display screen;
FIG. **3** is a front view of a third image in the sequence of the transitional graphical user interface on the display screen;
FIG. **4** is a front view of a fourth image in the sequence of the transitional graphical user interface on the display screen;
FIG. **5** is a front view of a fifth image in the sequence of the transitional graphical user interface on the display screen; and,
FIG. **6** is a front view of a sixth image in the sequence of the transitional graphical user interface on the display screen.

The appearance of the transitional graphical user interface of the embodiment sequentially transitions between the images shown in FIGS. **1-6**. The process or period in which one image transitions to another image forms no part of the claimed design. The broken line at the periphery of the figures illustrates the display screen, and the remaining broken lines illustrate portions of the transitional graphical user interface. None of the broken lines form part of the claimed design.

1 Claim, 6 Drawing Sheets





(56) **References Cited**

U.S. PATENT DOCUMENTS

D757,070	S *	5/2016	Dziuba	D14/486
D761,294	S *	7/2016	Weeresinghe	D14/486
D761,828	S *	7/2016	Koeten	D14/486
D762,232	S *	7/2016	Howard	D14/486
D764,506	S *	8/2016	Rathke	D14/486
9,423,920	B2 *	8/2016	Brunswig	G06F 3/0481
D768,152	S *	10/2016	Gutierrez	D14/485
D770,480	S *	11/2016	Wielgosz	D14/486
D789,977	S *	6/2017	Mijatovic	D14/488
D809,550	S *	2/2018	Bray	D14/486
D819,071	S *	5/2018	Rathke	D14/487
D830,382	S *	10/2018	Marohn	D14/486
2013/0111388	A1 *	5/2013	Togami	G16H 50/50 715/771

OTHER PUBLICATIONS

Medium | 6 Web Apps . . . , posted on Apr. 8, 2019, no copyright date posted [online], [site visited Aug. 15, 2019]. Available from Internet, <URL: https://medium.com/@team_62166/6-web-apps-you-can-start-building-right-away-with-argon-dashboard-pro-laravel-578b8c7e3720/>.*

* cited by examiner


ipLEXUS
Hello,
Glossary
Check Your Workplace
Go To Dashboard
Logout
Search Keywords
Create Alert
SHOW RESULTS

FIG. 1


ipLEXUS
Hello,
Glossary
Check Your Workplace
Go To Dashboard
Logout
Search Keywords
erbitux cancer
Create Alert
SHOW RESULTS
Search Crumbs
Erbitux
and
Cancer
Cetuximab(intervention)
Results Summary
Mode of Analysis
Correlation
View Publication Trends
Indication
Intervention
Gene
Protein
Publications
Clinical Trials
Congresses
Thesis
Patents
News & Press Release
Grants
Treatment Guidelines
Sort: Recency
Filter by Year
Publications
PK220 Immunoligand rGP75-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma .
VIEW ABSTRACT
Publications
Immunotherapy for recurrent/metastatic head and neck cancer.
VIEW ABSTRACT
Publications
Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies
VIEW ABSTRACT

FIG. 2


Fetching Data
ipLEXUS
Hello,
Glossary
Check Your Workplace
Go To Dashboard
Logout

FIG. 3


Back to Current Search
History
Intervention: Active Ingradient
Drug Highlights
Trial Landscape
Recent Events
Previous
Next
Previous
Next
ipLEXUS
Hello,
Glossary
Check Your Workplace
Go To Dashboard
Logout

FIG. 4


Back to Current Search
Cetuximab
Intervention: Active Ingredient
Drug Highlights
Trial Landscape
Recent Events
History
Terminated
Have Results
Ongoing
Indication
Phase 0
Phase 1
Phase 2
Phase 3
Phase 4
Others
Trial Activity
Colorectal Carcinoma
Colorectal cancer metastatic
Squamous cell carcinoma of the head and neck
Cancer of Head and Neck
non-Small Cell Lung Carcinoma
Recurrent Neoplasm
Squamous cell carcinoma metastatic
Adenocarcinoma of rectum
Squamous cell Carcinoma
Malignant Squamous Cell Neoplasm
Previous
Next
ipLEXUS
Hello,
Glossary
Check Your Workplace
Go To Dashboard
Logout

FIG. 5


Back to Current Search
History
Intervention: Active Ingredient
Drug Highlights
Trial Landscape
Recent Events
Affimed Therapeutics' (AFMD) CEO Adi Hexes on Q4 2017 Results - Earnings Call Transcript | Seeking Alpha
Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018
Celcuity's (CELC) CEO Brian Sullivan on Q4 2017 Results - Earnings Call Transcript | Seeking Alpha
Global and USA Cancer Immunotherapy Market 2017-2022: This Space will be a Significant Revenue Generator (Excess of $30 Billion) for the Biopharmaceutical Industry by 2022
iPLEXUS
Hello,
Glossary
Check Your Workplace
Go To Dashboard
Logout

FIG. 6